Ebola vaccine from Glaxo passes early safety test
November 26, 2014 at 17:00 PM EST
NEW YORK, Nov 26 (Reuters) - An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects and produced an immune response in all 20 healthy volunteers who received it in an early-stage clinical trial, scientists reported on Wednesday in the New England Journal of Medicine.